Stay updated with breaking news from Exscientia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In its continued efforts to use AI to discover potential new drug candidates, then predict whether those therapies will work in an individual patient, the U.K.-based Exscientia has found a hometown hero to lead the charge.
By Colin Kellaher Shares of Exscientia PLC rose sharply in premarket trading Friday after the pharmatech company inked a research collaboration and license agreement potentially worth billions... | January 8, 2022
Sanofi is among the many pharmaceutical giants venturing into artificial intelligence to improve accuracy and reduce time spent on research.
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines Collaborative efforts aim to accelerate drug discovery and improve clinical
Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia's AI-based capabilities and personalised medicine platform from target identification